Drugs / AB002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03963895 | Jul 2019 → Dec 2020 | end stage renal failure, thrombotic disease | Aronora, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03963895 ↗ |
| Known as | E-WE thrombin | “AB002 (E-WE thrombin) is an investigational protein C activator thrombin analog in phase 2 clinical development” PMID 31977000 ↗ Feb 2020 |
| Action | Activate | “AB002 is an injectable protein C activating enzyme under investigation to safely prevent and treat thrombosis.” PMID 39060370 ↗ Jul 2024 |
| Modality | Protein / enzyme biologic | “AB002 is an injectable protein C activating enzyme under investigation to safely prevent and treat thrombosis.” PMID 39060370 ↗ Jul 2024 |
| Route | Intravenous | “AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion” NCT03963895 ↗ |